Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for High Tech Pharmaceuticals Co., Ltd. (106190:KRX), powered by AI.
High Tech Pharmaceuticals Co., Ltd. is currently trading at ₩13,810. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for High Tech Pharmaceuticals Co., Ltd. on Alpha Lenz.
High Tech Pharmaceuticals Co., Ltd.'s P/E ratio is 13.0.
“High Tech Pharmaceuticals Co., Ltd. trades at a P/E of 13.0 (undervalued) with solid ROE of 9.2%.”
Ask for details →High Tech Pharmaceuticals Co., Ltd. is a prominent player in the pharmaceutical industry, specializing in the research, development, and manufacturing of a wide array of healthcare products. Its primary function is to advance the field of medicine through innovative drug therapies and medical solutions designed to address various health conditions. High Tech Pharmaceuticals actively participates in numerous sectors including oncology, cardiology, and neurology, among others. This diverse focus allows the company to impact a broad spectrum of health challenges. The organization is known for its state-of-the-art research facilities and commitment to quality, adhering to strict regulatory standards in its operations. In the financial market, High Tech Pharmaceuticals holds a significant position, reflecting its reputation and influence in advancing medical science and delivering pharmaceutical solutions globally. The company's efforts in pioneering new treatment modalities and its collaborations with healthcare providers highlight its continuous contribution to the dynamic landscape of healthcare innovations.
“High Tech Pharmaceuticals Co., Ltd. trades at a P/E of 13.0 (undervalued) with solid ROE of 9.2%.”
Ask for details →High Tech Pharmaceuticals Co., Ltd. (ticker: 106190) is a company listed on KRX in the Healthcare sector (Drug Manufacturers - Specialty & Generic). Market cap is $148.8B.
The current price is ₩13,810 with a P/E ratio of 12.96x and P/B of 1.14x.
ROE is 9.17% and operating margin is 18.32%. Annual revenue is $70.2B.